Back to Search Start Over

Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.

Authors :
Larsen MK
Skov V
Kjær L
Eickhardt-Dalbøge CS
Knudsen TA
Kristiansen MH
Sørensen AL
Wienecke T
Andersen M
Ottesen JT
Gudmand-Høyer J
Snyder JA
Andersen MP
Torp-Pedersen C
Poulsen HE
Stiehl T
Hasselbalch HC
Ellervik C
Source :
Blood cancer journal [Blood Cancer J] 2024 Feb 09; Vol. 14 (1), pp. 28. Date of Electronic Publication: 2024 Feb 09.
Publication Year :
2024

Abstract

The neutrophil-to-lymphocyte ratio(NLR) is increased in chronic inflammation and myeloproliferative neoplasms (MPN). We hypothesize that NLR is associated with all-cause mortality and mortality by comorbidity burden in the general population and individuals with MPN. We included 835,430 individuals from The Danish General Suburban Population Study, general practitioners, and outpatient clinics. We investigated NLR on mortality stratified by prevalent and incident MPN, essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), comorbidity burden (CCI-score), and the Triple-A risk score using hazard ratio (HR) and 95% confidence interval (95%CI). NLR 1-1.9 was the reference level. During a median follow-up of 11.2 years, 197,802 deaths were recorded. All-cause mortality increased for a stepwise increasing NLR with a HR (95%CI) for NLR ≥ 6 of 2.06(2.03-2.09) for the whole population and 2.93(2.44-3.50) in prevalent MPN. ET, PV, and MF had a HR (95%CI) for NLR ≥ 2 of 2.14(1.71-2.69), 2.19(1.89-2.54), and 2.31(1.91-2.80). Results were similar for incident MPN. Mortality was higher for stepwise increasing NLR and CCI-score(p <subscript>interaction</subscript>  < 2×10 <superscript>-16</superscript> ), with a HR for NLR ≥ 6 of 2.23(2.17-2.29), 4.10(4.01-4.20), and 7.69(7.50-7.89), for CCI-score 0, 1-2, or ≥3. The Triple-A risk score demonstrated alignment with NLR. Increasing NLR and comorbidity burden were associated with lower survival in individuals without MPN but were even worse in prevalent and incident MPN, ET, PV, and MF.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
2044-5385
Volume :
14
Issue :
1
Database :
MEDLINE
Journal :
Blood cancer journal
Publication Type :
Academic Journal
Accession number :
38331919
Full Text :
https://doi.org/10.1038/s41408-024-00994-z